• 主页
  • 查找结果
  • Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

Cancer chemotherapy and pharmacology (2015-01-02)
Yaping Liu, Xiaoyan Zhang, Songlin An, Yanli Wu, Guofu Hu, Yunxia Wu
摘要

To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expression in normal and cancerous cervical tissues and to determine its correlation with clinical and pathologic presentations of cervical cancers. The anti-cervical cancer activity of neamine was assessed both in vitro and in vivo. After intravenous (i.v.) administration of 15, 30, and 60 mg kg(-1) neamine, the pharmacokinetic parameters were as follows: AUC(0-t), 9,398.0 ± 653.4, 19,235.2 ± 2,939.0, and 35,437.7 ± 3,772.2 mg L(-1) min; C max, 170.8 ± 13.1, 353.3 ± 15.8, and 464.0 ± 33.1 mg L(-1); T 1/2, 34.9 ± 4.1, 46.8 ± 5.1, and 58.0 ± 12.5 min, respectively. The bioavailability of neamine administered through intramuscular, subcutaneous, intraperitoneal and intragastric route was 14.0 ± 3.0, 8.4 ± 0.6, 6.5 ± 3.3, and 3.1 ± 0.2 %, respectively. Up-regulated ANG expression and increased nuclear translocation were observed in cervical cancers as compared to normal cervical tissues. Moreover, upregulation of ANG was positively correlated with primary tumor invasion. Neamine inhibited ANG-induced HUVEC and HeLa cell proliferation as well as nuclear translocation of ANG. Consistently, neamine inhibited both the establishment and progression of xenograft human cervical cancers in athymic mice. The bioavailability of neamine administered through extravascular routes was low. The half-life of neamine through i.v. administration was short. This suggests that a higher dosing frequency in order to maintain a therapeutic effect. Neamine holds potential against cervical cancer. The mechanisms of neamine inhibition are through blocking nuclear translocation of ANG thereby inhibiting both angiogenesis and cancer cell proliferation.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, 99.93%
Supelco
甲醇, analytical standard
Supelco
甲酸铵, eluent additive for LC-MS, LiChropur, ≥99.0%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲酸铵, reagent grade, 97%
Sigma-Aldrich
甲酸铵, ≥99.995% trace metals basis
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲酸铵, BioUltra, ≥99.0% (calc. based on dry substance, NT)
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甲酸铵 溶液, BioUltra, 10 M in H2O
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
五氟丙酸, 97%
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, Absolute - Acetone free
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Supelco
甲酸铵 溶液, 10 mM in H2O, suitable for HPLC
Supelco
甲醇 溶液, contains 0.10 % (v/v) formic acid, UHPLC, suitable for mass spectrometry (MS), ≥99.5%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Supelco
甲醇 溶液, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 5 mm × 8 in.
Sigma-Aldrich
甲醇, NMR reference standard
Sigma-Aldrich
甲醇 溶液, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 3 mm × 8 in.